In Vivo Purging With Rituximab Prior to Stem Cell Collection Is Associated With Persistent Molecular Evidence of t(14;18) That Often Disappears Post-Transplant in Patients With Follicular Lymphoma
ByR. J. Buckstein,K. Imrie,D. Spaner,L. Bordeleau,T. Tompkins,E. Iakhnina,N. Pennell,A. Coovadia,M. Reis,K. Hewitt,P. Richardson,A. Lima,J. B. Robinson,M. Lim,B. Ordonez-Perez,N. L. Berinstein
Published: | Updated:
We previously reported that “in vivo purging” with rituximab (Rituxan) during stem-cell collection is safe and does not adversely affect engraftment. We now report on our transplant experience with rituximab. From June 1998 to December